Cerus Corp.
Company Overview
Cerus Corporation is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by inactivating blood-borne pathogens in donated blood components intended for transfusion. The company's primary products are used to treat platelets and plasma.
The company's technology helps ensure the safety of blood transfusions by eliminating various pathogens and harmful substances from blood components before they are given to patients. This is particularly important for preventing the transmission of diseases through blood transfusions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $50.66m | $53.88m | - | $2.26m | 0.00% | 4.19% |
| June 30, 2024 | $50.52m | $56.69m | - | $2.33m | 0.00% | 4.11% |
| March 31, 2024 | $43.4m | $53.61m | - | $2.23m | 0.00% | 4.17% |
Company Impact
Help us evaluate Cerus Corp.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.